Title
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients
Date Issued
01 August 2018
Access level
open access
Resource Type
journal article
Author(s)
Restrepo M.I.
Babu B.L.
Reyes L.F.
Chalmers J.D.
Soni N.J.
Sibila O.
Faverio P.
Rodriguez-Cintron W.
Aliberti S.
Aruj P.K.
Attorri S.
Barimboim E.
Caeiro J.P.
Garzón M.I.
Cambursano V.H.
Ceccato A.
Chertcoff J.
Lascar F.
Di Tulio F.
Díaz A.C.
de Vedia L.
Ganaha M.C.
Lambert S.
Lopardo G.
Luna C.M.
Malberti A.G.
Morcillo N.
Tartara S.
Pensotti C.
Pereyra B.
Scapellato P.G.
Stagnaro J.P.
Shah S.
Lötsch F.
Thalhammer F.
Anseeuw K.
Francois C.A.
Van Braeckel E.
Vincent J.L.
Djimon M.Z.
Bashi J.
Dodo R.
Nouér S.A.
Chipev P.
Encheva M.
Miteva D.
Petkova D.
Dodo Balkissou A.
Pefura Yone E.W.
Mbatchou Ngahane B.H.
Shen N.
Xu J.F.
Bustamante Rico C.A.
Buitrago R.
Pereira Paternina F.J.
Kayembe Ntumba J.M.
Carevic V.V.
Jakopovic M.
Jankovic M.
Matkovic Z.
Mitrecic I.
Bouchy Jacobsson M.L.
Bro Christensen A.
Heitmann Bødtger U.C.
Niels Meyer C.
Vestergaard Jensen A.
Baunbæk-Knudsen G.
Petersen P.T.
Andersen S.
Abd El-Wahhab I.E.
Elsayed Morsy N.
Shafiek H.
Sobh E.
Abdella Abdulsemed K.
Bertrand F.
Brun-Buisson C.
de Montmollin E.
Fartoukh M.
Messika J.
Tattevin P.
Khoury A.
Ebruke B.
Dreher M.
Kolditz M.
Meisinger M.
Pletz M.W.
Hagel S.
Rupp J.
Schaberg T.
Spielmanns M.
Creutz P.
Suttorp N.
Siaw-Lartey B.
Dimakou K.
Papapetrou D.
Tsigou E.
Ampazis D.
Kaimakamis E.
Bhatia M.
University of Barcelona
Publisher(s)
European Respiratory Society
Abstract
Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
Volume
52
Issue
2
Language
English
Scopus EID
2-s2.0-85051459272
PubMed ID
Source
European Respiratory Journal
ISSN of the container
09031936
Sponsor(s)
Acknowledgements: We would like to thank the European Respiratory Society, the World Federation of Societies of Intensive and Critical Care Medicine, the American College of Chest Physicians, the Asociación Latinoamericana de Tórax and the Sociedad Argentina de Infectología for their support of this project.
Support statement: This project was unfunded. However, Nilam Soni’s time is partially funded by the Department of Veterans Affairs, Quality Enhancement Research Initiative (QUERI) Partnered Evaluation Initiative Grant (HX002263-01A1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, nor the United States Government.
Sources of information:
Directorio de Producción Científica
Scopus